P/E ratio for Aeterna Zentaris (AEZS)
P/E ratio as of July 2025 (TTM): -2.79
According to Aeterna Zentaris's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.79173. At the end of 2022 the company had a P/E ratio of -0.1028.
P/E ratio history for Aeterna Zentaris from 2018 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.1028 | -55.99% |
| 2021 | -0.2335 | 33.62% |
| 2020 | -0.1748 | 511.66% |
| 2019 | -0.0286 | -168.13% |
| 2018 | 0.0419 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Spectrum Pharmaceuticals
SPPI | -2.86 | 2.49% | 🇺🇸 USA |
 Novartis NVS | 19.0 | -779.08% | 🇨🇭 Switzerland |
 Bristol-Myers Squibb BMY | 17.5 | -727.12% | 🇺🇸 USA |
 Sanofi SNY | 17.0 | -707.67% | 🇫🇷 France |
 Halozyme Therapeutics HALO | 14.0 | -602.41% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.